The Angiotensin Type 1 Receptor: A Drug Target to Reduce the Risk of Organ Transplant Rejection

Title:The Angiotensin Type 1 Receptor: A Drug Target to Reduce the Risk of Organ Transplant Rejection

Volume: 21 Issue: 13

Author(s): Alireza Moslem, Mohsen Aliakbarian, Rozita Khodashahi, Mahmoud Tavakkoli, Gordon A. Ferns, Hoda Rahimi, Kiarash Ashrafzade and Mohammad-Hassan Arjmand*

Affiliation:

• Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Keywords: Organ transplant rejection, angiotensin II, angiotensin type 1-receptor, inflammation, fibrosis, pro-fibrotic molecules.

Abstract: Allograft rejection is one of the main problems that must be overcome. Evidence suggests a role of the local renin-angiotensin system (RAS) in the progress of chronic allograft injury. Angiotensin II, generated by the renin-angiotensin system, is well-known as a major regulator molecule to control the blood pressure and fluid system. Evidence suggests that this bioactive molecule and its receptor increase the risk of tissue injuries and organ transplant rejection through different molecular mechanisms such as activation of innate and cellular immunity, upregulation of inflammatory pathways, and accumulation of extracellular matrix by expression pro-fibrotic molecules like transforming growth factor β (TGF-β) to increase the risk of fibrosis. Based on these findings, AT1R antagonists might have therapeutic potential to prevent the risk of tissue injuries and allograft rejection by regulating immune response, inflammation pathway, and fibrogenesis to improve organ functions.

Cite this article as:

Moslem Alireza, Aliakbarian Mohsen, Khodashahi Rozita, Tavakkoli Mahmoud, Ferns A. Gordon, Rahimi Hoda, Ashrafzade Kiarash and Arjmand Mohammad-Hassan*, The Angiotensin Type 1 Receptor: A Drug Target to Reduce the Risk of Organ Transplant Rejection, Letters in Drug Design & Discovery 2024; 21 (13) . https://dx.doi.org/10.2174/1570180820666230915103737